Veracyte, Inc. (VCYT)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 32.97 |
| Open | 33.00 |
| Bid | 32.81 x 200 |
| Ask | 32.90 x 100 |
| Day's Range | 32.48 - 33.91 |
| 52 Week Range | 18.61 - 35.51 |
| Volume | |
| Avg. Volume | 933,315 |
| Market Cap | 2.523B |
| Beta (5Y Monthly) | 1.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
SOUTH SAN FRANCISCO, Calif., October 02, 2024--New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men.
- Business Wire
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
SOUTH SAN FRANCISCO, Calif., September 15, 2024--New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
- Business Wire
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
SOUTH SAN FRANCISCO, Calif., September 04, 2024--Veracyte appoints Brent Shafer and Tom Miller, Ph.D., to its board of directors.
© 2024 Yahoo. All rights reserved.